Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.

[1]  I. Spigelman,et al.  Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain , 2018, Pain.

[2]  C. France,et al.  Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed‐dose ratio , 2018, European journal of pharmacology.

[3]  D. Morgan,et al.  Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain , 2017, Molecular pain.

[4]  V. Petrucci,et al.  Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage , 2017, Scientific Reports.

[5]  Eric T. Kool,et al.  Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis. , 2017, Chemical reviews.

[6]  David P. Roberson,et al.  Breaking barriers to novel analgesic drug development , 2017, Nature Reviews Drug Discovery.

[7]  B. Betz-Stablein,et al.  Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis , 2017, Neuropsychopharmacology.

[8]  E. Novellino,et al.  Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors , 2017, Journal of enzyme inhibition and medicinal chemistry.

[9]  C. Vaughan,et al.  Opioid and cannabinoid synergy in a mouse neuropathic pain model , 2016, British journal of pharmacology.

[10]  A. Keresztes,et al.  Investigation of receptor binding and functional characteristics of hemopressin(1–7) , 2016, Neuropeptides.

[11]  Z. Xi,et al.  Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus , 2016, Neuron.

[12]  H. Buschmann,et al.  New approaches to treating pain. , 2016, Bioorganic & medicinal chemistry letters.

[13]  E. Novellino,et al.  The design of multitarget ligands for chronic and neuropathic pain. , 2015, Future medicinal chemistry.

[14]  Szilvia Veszelka,et al.  Tesmilifene modifies brain endothelial functions and opens the blood–brain/blood–glioma barrier , 2015, Journal of neurochemistry.

[15]  Martin Nimczick,et al.  New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds , 2015, ChemMedChem.

[16]  V Kiran Vemuri,et al.  Medicinal chemistry of cannabinoids , 2015, Clinical pharmacology and therapeutics.

[17]  C. France,et al.  Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[18]  M. Spetea,et al.  Synthesis and pharmacological evaluation of [(3)H]HS665, a novel, highly selective radioligand for the kappa opioid receptor. , 2015, ACS chemical neuroscience.

[19]  C. France,et al.  Impact of Efficacy at the μ-Opioid Receptor on Antinociceptive Effects of Combinations of μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[20]  Martin J. Lohse,et al.  G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives , 2014, Pharmacological Reviews.

[21]  J. Desroches,et al.  Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia , 2014, Neuroscience.

[22]  J. Wiley,et al.  Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. , 2014, Life sciences.

[23]  F. Rodríguez de Fonseca,et al.  Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results , 2014, Drug design, development and therapy.

[24]  R. Dubner,et al.  Osteoarthritis pain mechanisms: basic studies in animal models. , 2013, Osteoarthritis and cartilage.

[25]  P. Portoghese,et al.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. , 2013, Journal of medicinal chemistry.

[26]  C. France,et al.  Interactions between μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists in Rhesus Monkeys: Antinociception, Drug Discrimination, and Drug Self-Administration , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[27]  B. Lutz,et al.  Identification and Quantification of a New Family of Peptide Endocannabinoids (Pepcans) Showing Negative Allosteric Modulation at CB1 Receptors* , 2012, The Journal of Biological Chemistry.

[28]  G. Horváth,et al.  Characterization of antinociceptive potency of endomorphin-2 derivatives with unnatural amino acids in rats. , 2012, Acta physiologica Hungarica.

[29]  P. Chameau,et al.  Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.

[30]  G. Benedek,et al.  The antinociceptive potency of N-arachidonoyl-dopamine (NADA) and its interaction with endomorphin-1 at the spinal level , 2011, Pharmacology Biochemistry and Behavior.

[31]  V. Hruby,et al.  New potent biphalin analogues containing p-fluoro-l-phenylalanine at the 4,4′ positions and non-hydrazine linkers , 2011, Amino Acids.

[32]  W. Kim,et al.  Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model , 2011, Neuroscience Letters.

[33]  W. Leppert.  Pain Management in Patients with Cancer: Focus on Opioid Analgesics , 2011, Current pain and headache reports.

[34]  J. Desroches,et al.  Opioids and cannabinoids interactions: involvement in pain management. , 2010, Current drug targets.

[35]  L. Devi,et al.  Cannabinoid-opioid interactions during neuropathic pain and analgesia. , 2010, Current opinion in pharmacology.

[36]  R. Lindigkeit,et al.  Spice: a never ending story? , 2009, Forensic science international.

[37]  Á. Kittel,et al.  A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes , 2009, Neurochemistry International.

[38]  Ronald T. Raines,et al.  Hydrolytic stability of hydrazones and oximes. , 2008, Angewandte Chemie.

[39]  C. France,et al.  Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociception , 2008, Psychopharmacology.

[40]  M. Narita,et al.  Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine , 2008, Neuropsychopharmacology.

[41]  R. L. Pagano,et al.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors , 2007, Proceedings of the National Academy of Sciences.

[42]  D. Selley,et al.  Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. , 2007, European journal of pharmacology.

[43]  D. Lambert,et al.  Medicinal Chemistry Endeavors around the Phytocannabinoids , 2007, Chemistry & biodiversity.

[44]  S. Welch,et al.  Synergy between Δ9-tetrahydrocannabinol and morphine in the arthritic rat , 2007 .

[45]  E. Kalso,et al.  Antinociception by Spinal and Systemic Oxycodone: Why Does the Route Make a Difference?: In Vitro and In Vivo Studies in Rats , 2006, Anesthesiology.

[46]  J. Manzanares,et al.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. , 2006, Current neuropharmacology.

[47]  D. Andreu,et al.  Iodination of proteins by IPy2BF4, a new tool in protein chemistry. , 2006, Biochemistry.

[48]  John D. Roberts,et al.  Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. , 2006, European journal of pharmacology.

[49]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[50]  Maree T. Smith,et al.  Co-administration of oxycodone and morphine and analgesic synergy re-examined. , 2005, British journal of clinical pharmacology.

[51]  J. Angus,et al.  Synergistic and additive interactions of the cannabinoid agonist CP55,940 with μ opioid receptor and α2‐adrenoceptor agonists in acute pain models in mice , 2005, British journal of pharmacology.

[52]  Masami Niwa,et al.  Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology , 2005, Cellular and Molecular Neurobiology.

[53]  G. Hynd,et al.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. , 2005, Bioorganic & medicinal chemistry.

[54]  M. J. Field,et al.  The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? , 2004, Neuroscience Letters.

[55]  M. Aceto,et al.  Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. , 2004, Experimental and clinical psychopharmacology.

[56]  D. Finn,et al.  Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain , 2004, The European journal of neuroscience.

[57]  R. E. Guzman,et al.  Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. , 2003, Osteoarthritis and cartilage.

[58]  T. Freund,et al.  Role of endogenous cannabinoids in synaptic signaling. , 2003, Physiological reviews.

[59]  S. Welch,et al.  Modulation of Oral Morphine Antinociceptive Tolerance and Naloxone-Precipitated Withdrawal Signs by Oral Δ9-Tetrahydrocannabinol , 2003, Journal of Pharmacology and Experimental Therapeutics.

[60]  Erin A. Mccarthy,et al.  Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration , 2003, Journal of Pharmacology and Experimental Therapeutics.

[61]  Ming-Jung Wu,et al.  3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB(1) cannabinoid receptor. , 2003, Bioorganic & medicinal chemistry.

[62]  A. Péter,et al.  In vitro quantitative study of the degradation of endomorphins , 2002, Peptides.

[63]  T. Kaneko,et al.  CB1-cannabinoid and μ-opioid receptor co-localization on postsynaptic target in the rat dorsal horn , 2001, Neuroreport.

[64]  V. Pickel,et al.  Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus , 2001, The Journal of Neuroscience.

[65]  Ming-Jung Wu,et al.  Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. , 2000, Drug and alcohol dependence.

[66]  V. Chapman.  The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat , 1999, British journal of pharmacology.

[67]  S. Welch,et al.  Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. , 1999, The Journal of pharmacology and experimental therapeutics.

[68]  J. Hanoune,et al.  Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. , 1999, Life sciences.

[69]  H. Fields,et al.  An analgesia circuit activated by cannabinoids , 1998, Nature.

[70]  D. R. Compton,et al.  Structure-activity relationships of indole- and pyrrole-derived cannabinoids. , 1998, The Journal of pharmacology and experimental therapeutics.

[71]  A. Jacklin,et al.  Pain relief with oral cannabinoids in familial Mediterranean fever , 1997, Anaesthesia.

[72]  R. Shank,et al.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. , 1995, The Journal of pharmacology and experimental therapeutics.

[73]  D. Selley,et al.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  L. Gold,et al.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.

[75]  S. Welch,et al.  Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. , 1992, The Journal of pharmacology and experimental therapeutics.

[76]  A. Konecka,et al.  Double-enkephalins—Synthesis, activity on guinea-pig ileum, and analgesic effect , 1982, Peptides.

[77]  L. Stein,et al.  Potent analgesic activity of the enkephalin-like tetrapeptide H-Tyr-D-Ala-Gly-Phe-NH2. , 1978, Life sciences.

[78]  C. Sandman,et al.  Increased analgesic activities of a fluorinated and a dimeric analogue of [D-Ala-2]-methionine enkephalinamide. , 1978, Biochemical and biophysical research communications.

[79]  Discriminative Stimulus , 2021, Encyclopedia of Autism Spectrum Disorders.

[80]  Y. Uezono,et al.  mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. , 2008, Journal of pharmacological sciences.

[81]  S. Nikas,et al.  Structural requirements for cannabinoid receptor probes. , 2005, Handbook of experimental pharmacology.

[82]  M. Eissenstat,et al.  Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. , 1992, Journal of medicinal chemistry.

[83]  Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .